GSK agrees $10 billion deal for Nuvalent cancer drugs | Opinion – Chemistry World

But companies were beginning to develop a new class of antibodies that could target immune checkpoint inhibitors. This was built on research into …

Read more here

Ready to collaborate or learn more about our services?

Find out how we can support your business.

Scroll to Top